News -

Euro Diagnostica is now launching a TLR4 responsive cell line, strengthening the iLite™ Assay Ready Cell portfolio within inflammation.

Toll-like receptor 4 (TLR4) plays a fundamental role in the activation of the innate immune response, which is why drug development of TLR4 antagonists is a hot topic for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis.

Euro Diagnostica is proud to presents a new, highly specific and sensitive reporter gene cell line, responsive to stimulation of TLR4.

The iLite™ TLR4 cell line is launched as Assay Ready Cells, which can be utilized for determining functional activity of potential TLR4 antagonists and agonists. The cells express Firefly Luciferase under the control of a TLR4 responsive promotor and when stimulating the cells with e.g. LPS, the resulting luminescent signal is proportional to the functional activation of TLR4.

Conversely, in an inhibition assay, the cells can be utilized for determining a TLR4 antagonist's ability to block the signaling and activation of TLR4.

Contact us today to find out more about iLite™ Assay Ready Cells!

Related links

Topics

  • Diseases

Categories

  • ilite cell-based assays
  • product
  • corporate

Contacts

Trine Österbye

VP Biopharma Solutions iLite Cell-based Assays +46 40 53 76 47

Related content

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

Latest addition to Euro Diagnostica’s portfolio of iLite™ Assay Ready Cells within inflammation: iLite™ GM-CSF Assay Ready Cells!

The growth factor GM-CSF (Granulocyte-macrophage colony stimulating factor) has shown to be a key player in inflammation and autoimmunity. Assay Ready Cells targeting GM-CSF have been developed by Euro Diagnostica (Biomonitor) and are expected to be a useful tool in the drug development process for treatment of inflammatory and autoimmune diseases.